Self-injectable epinephrine for first-aid management of anaphylaxis. Export

@article{citeulike:2901157, abstract = {Anaphylaxis is a severe, potentially fatal systemic allergic reaction that is rapid in onset and may cause death. Epinephrine is the primary medical therapy, and it must be administered promptly. This clinical report focuses on practical issues concerning the administration of self-injectable epinephrine for first-aid treatment of anaphylaxis in the community. The recommended epinephrine dose for anaphylaxis in children, based primarily on anecdotal evidence, is 0.01 mg/kg, up to 0.30 mg. Intramuscular injection of epinephrine into the lateral thigh (vastus lateralis) is the preferred route for therapy in first-aid treatment. Epinephrine autoinjectors are currently available in only 2 fixed doses: 0.15 and 0.30 mg. On the basis of current, albeit limited, data, it seems reasonable to recommend autoinjectors with 0.15 mg of epinephrine for otherwise healthy young children who weigh 10 to 25 kg (22-55 lb) and autoinjectors with 0.30 mg of epinephrine for those who weigh approximately 25 kg (55 lb) or more; however, specific clinical circumstances must be considered in these decisions. This report also describes several quandaries in regard to management, including the selection of dose, indications for prescribing an autoinjector, and decisions regarding when to inject epinephrine. Effective care for individuals at risk of anaphylaxis requires a comprehensive management approach involving families, allergic children, schools, camps, and other youth organizations. Risk reduction entails confirmation of the trigger, discussion of avoidance of the relevant allergen, a written individualized emergency anaphylaxis action plan, and education of supervising adults with regard to recognition and treatment of anaphylaxis.}, author = {Sicherer, S. H. and Simons, F. E. and {}}, citeulike-article-id = {2901157}, citeulike-linkout-0 = {http://dx.doi.org/10.1542/peds.2006-3689}, citeulike-linkout-1 = {http://view.ncbi.nlm.nih.gov/pubmed/17332221}, citeulike-linkout-2 = {http://www.hubmed.org/display.cgi?uids=17332221}, doi = {10.1542/peds.2006-3689}, issn = {1098-4275}, journal = {Pediatrics}, keywords = {anaphylaxis, epinephrine}, month = {March}, number = {3}, pages = {638--646}, posted-at = {2008-06-17 05:39:56}, priority = {2}, title = {Self-injectable epinephrine for first-aid management of anaphylaxis.}, url = {http://dx.doi.org/10.1542/peds.2006-3689}, volume = {119}, year = {2007} }

TY - JOUR ID - citeulike:2901157 L3 - citeulike-article-id:2901157 N2 - Anaphylaxis is a severe, potentially fatal systemic allergic reaction that is rapid in onset and may cause death. Epinephrine is the primary medical therapy, and it must be administered promptly. This clinical report focuses on practical issues concerning the administration of self-injectable epinephrine for first-aid treatment of anaphylaxis in the community. The recommended epinephrine dose for anaphylaxis in children, based primarily on anecdotal evidence, is 0.01 mg/kg, up to 0.30 mg. Intramuscular injection of epinephrine into the lateral thigh (vastus lateralis) is the preferred route for therapy in first-aid treatment. Epinephrine autoinjectors are currently available in only 2 fixed doses: 0.15 and 0.30 mg. On the basis of current, albeit limited, data, it seems reasonable to recommend autoinjectors with 0.15 mg of epinephrine for otherwise healthy young children who weigh 10 to 25 kg (22-55 lb) and autoinjectors with 0.30 mg of epinephrine for those who weigh approximately 25 kg (55 lb) or more; however, specific clinical circumstances must be considered in these decisions. This report also describes several quandaries in regard to management, including the selection of dose, indications for prescribing an autoinjector, and decisions regarding when to inject epinephrine. Effective care for individuals at risk of anaphylaxis requires a comprehensive management approach involving families, allergic children, schools, camps, and other youth organizations. Risk reduction entails confirmation of the trigger, discussion of avoidance of the relevant allergen, a written individualized emergency anaphylaxis action plan, and education of supervising adults with regard to recognition and treatment of anaphylaxis. IS - 3 JF - Pediatrics SN - 1098-4275 EP - 646 TI - Self-injectable epinephrine for first-aid management of anaphylaxis. VL - 119 SP - 638 KW - anaphylaxis KW - epinephrine AU - Sicherer, SH AU - Simons, FE PY - 2007/03// UR - http://dx.doi.org/10.1542/peds.2006-3689 ER -